The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Provision for product warranties | - | 214 | - | - |
| Allowance for credit losses | - | 137 | 130 | 156 |
| Loss on disposal of property and equipment | - | 0 | -19 | 0 |
| Net loss | -2,143 | -1,240 | -1,955 | -7,910 |
| Depreciation and amortization | 202 | 221 | 164 | 270 |
| Provision for inventory obsolescence | 10 | 136 | 33 | 172 |
| Stock-based compensation | 312 | 500 | 530 | 971 |
| Non-cash lease expense | 20 | 18 | 20 | 48 |
| Non-cash interest expense | 238 | 242 | 242 | 472 |
| Trade receivables | -3,952 | 3,895 | 1,836 | -4,413 |
| Prepaid expenses and other assets | 148 | -228 | 425 | -434 |
| Inventories | 845 | -511 | 865 | 720 |
| Accounts payable | -411 | -155 | 328 | 182 |
| Accrued expenses and other liabilities | -1,759 | 553 | 79 | -423 |
| Net cash used in operating activities | -572 | -2,530 | -3,536 | -1,935 |
| Purchases of property and equipment | -779 | - | 519 | 320 |
| Net cash used in investing activities | 779 | - | -519 | -320 |
| Proceeds from stock option exercises | 39 | - | 49 | - |
| Repayment of finance lease liabilities | -9 | - | 4 | 10 |
| Contributions from non-controlling interest | -60 | - | 0 | 60 |
| Net cash provided by financing activities | -12 | - | 45 | 50 |
| Effect of exchange rates on cash | 337 | - | -156 | -235 |
| Net change in cash and cash equivalents | -603 | 6,605 | -4,166 | -2,440 |
| Cash and cash equivalents, beginning of period | 31,740 | 25,135 | 31,741 | - |
| Cash and cash equivalents, end of period | 31,137 | 31,740 | 25,135 | - |
Apyx Medical Corp (APYX)
Apyx Medical Corp (APYX)